|
Symposium
[In-Person] Advances in Cancer Therapeutics
Speakers:
Alex Cacovean (Biomea Fusion), Eric Blouin, (Ipsos), Umer Raffat (Evercore), Amar Patel (BMS), Kelsey Gauthier (Arcus), Allison Roberts (Frontier Medicines), Jennifer Low (23andMe), Shiva Bhowmik (Trio Pharmaceuticals), Dirk Brockstedt (RAPT Therapeutics), Dara L. Burdette (Tempest Therapeutics), Cheng Liu (Eureka Therapeutics)
Organizers:
Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date:
2023-09-21
Time:
8:45-18:30 Pacific Time
Registration fee:
Regular attendees: $195; Academic/Students/Postdocs/Between Jobs: $95; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $995; Lunch Sponsorship: $1250; On-site Registration:$500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(13)Aragen; ATUM; Biocytogen Boston Corp; Correlia Biosystems Inc; Curis Decontamination Systems; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Inotiv; Meadowhawk Biolabs; PharmaBlock; Revvity; SOLVO/CRL
Registration: http://www.PBSS.org
Registration deadline:2023-09-19
(it will close sooner if the seating cap is reached)
About the Topic
This one-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.
Presenting Companies / Speakers:
- Bristol Myers Squibb-Amar Patel, MD, Senior Director, Early Clinical Development: Advancing Novel Modalities for the Treatment of Hematologic Cancers
- Arcus-Kelsey Gauthier, PhD, Director of Biology: Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells.
- Biomea Fusion-Alex Cacovean, MD, VP, Clinical Development: First-in-Class Covalent MENIN Inhibitors for AML.
- Evercore ISI-Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director: ASCO Highlights.
- Ipsos Healthcare-Eric Blouin, SVP of Oncology: New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
- Frontier Medicines-Allison Roberts, PhD, Senior Scientist,Chemical Biology: Challenging Cancer with Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor.
- 23andMe-Jennifer Low, MD, PhD, Head of Therapeutics Development: Developing genetically-validated drugs using 23andMe's genetic database.
- Trio Pharmaceuticals-Shiva Bhowmik, PhD, founder nad COO: Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity.
- RAPT Therapeutics-Dirk Brockstedt, PhD, Chief Scientific Officer: CCR4 oncology program update
- Tempest Therapeutics-Dara L. Burdette, PhD, Executive Director: Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
- Eureka Therapeutics-Cheng Liu, PhD, Founder, President and CEO: Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Morning Sessions:
Time (PT)
|
Topic
|
8:45-9:00 am
|
PBSS Welcome and Symposium Overview, Shichang Miao (PBSS)
|
9:00-9:35 am
|
1. Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells
Kelsey Gauthier, PhD, Director of Biology, Arcus Biosciences
|
9:35-10:10 am
|
2. Developing Genetically-Validated Drugs Using 23andMe’s Genetic Database
Jennifer Low, MD, PhD, Head of Therapeutics Development, 23andMe
|
10:10-10:45 am
|
3. Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor
Allison Roberts, PhD, Senior Scientist, Chemical Biology, Frontier Medicines
|
10:45-10:55 am
|
Major Sponsor’s Presentation (Fortrea CRO)
|
10:55-11:15 am
|
Break Period & Vendor Show
|
11:15-11:50 am
|
4. First-in-Class Covalent MENIN Inhibitors for AML
Alex Cacovean, MD, VP, Clinical Development, Biomea Fusion
|
11:50-12:25 pm
|
5. New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
Eric Blouin, SVP Oncology, Ipsos Healthcare
|
12:25-1:15 pm
|
Lunch
|
Afternoon Sessions:
Time (PT)
|
Topic
|
1:15-1:50 pm
|
6. ASCO Highlights
Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director, Evercore ISI
|
1:50-2:25 pm
|
7. Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity
Shiva Bhowmik, PhD, Founder & COO, Trio Pharmaceuticals
|
2:25-3:00 pm
|
8. Advancing Novel Modalities for the Treatment of Hematologic Cancers
Amar Patel, MD, Senior Director, Early Clinical Development, Bristol Myers Squibb
|
3:00-3:20 pm
|
Break
|
3:20-3:55 pm
|
9. Updates on CCR4 Antagonists for Oncology
Dirk Brockstedt, PhD, Chief Scientific Officer, RAPT Therapeutics
|
3:55-4:30 pm
|
10. Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
Dara L. Burdette, PhD, Executive Director, Tempest Therapeutics
|
4:30-5:05 pm
|
11. Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Cheng Liu, PhD, Founder, President and CEO, Eureka Therapeutics
|
5:05-5:35 pm
|
Panel Discussion (All Speakers)
|
5:35-6:30 pm
|
Happy Hour (sponsored by Alturas Analytics)
|
2025-02-13, [Free Online] The Science and Stories of Promising Biotech Startups
|
2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
|
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
|
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
|
2025-04-01, [For vendors ONLY] Seattle PBSS Seminar Luncheon Vendor Show
|
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
|
2025-04-22, [Free Online Workshop] Career Transitions for Research Scientists: BD/Sales in CROs, CDMOs, and Lab Products & Instruments
|
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
|
2025-05-05, [Free Online] Highlights of 2024 FDA Drug Approvals
|
2025-05-12, [In-Person] Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development
|
2025-06-02, [In-Person] Metabolism and Transport-mediated Drug-Drug Interaction: Current Practices, Regulatory Guidances, and Their Impact on Drug Development
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Allucent
Experts bringing development innovation w/ClinPharm Modeling & Simulation deliverables to inform dose, study design, modeling+development strategies.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|